このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

MediPD: An Online Mediterranean Diet Program for People Living With Parkinson's Disease (MediPD)

2026年10月22日 更新者:Claire McEvoy、Queen's University, Belfast

Feasibility Of An Online Self-management Mediterranean Diet Program To Improve Dietary Behaviour And Quality Of Life For People Living With Parkinson's Disease: The MediPD Pilot Randomised Controlled Trial

The aim of this pilot study is to assess whether an online Mediterranean diet programme called MediPD is acceptable and practical for people living with Parkinson's disease, and whether it can help them make and maintain changes towards a Mediterranean-style diet.

The study will include 120 adults living in the United Kingdom with Parkinson's disease who have access to an internet-enabled device and currently have low adherence to a Mediterranean-style diet. Participants will be randomly assigned to one of two groups. One group will receive access to the MediPD online programme, which includes short educational videos, personalised dietary information, practical resources, goal-setting tools, and online dietetic support. The other group will continue with their usual care and will receive access to MediPD after completing the final study assessment.

Researchers will compare the groups to see whether MediPD improves adherence to a Mediterranean diet after 24 weeks. The study will also examine dietary intake, non-motor symptoms, quality of life, gastrointestinal symptoms, cognitive function, and how acceptable and practical the programme is to use. Assessments will take place at the start of the study, at 12 weeks, and at 24 weeks.

調査の概要

研究の種類

介入

入学 (推定)

120

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Nicola A Ward, PhD, MSci
  • 電話番号:+44(0)7823368444
  • メール:medipd@qub.ac.uk

研究連絡先のバックアップ

  • 名前:Sinead O'Hagan, MSc
  • 電話番号:+44(0)7823368444
  • メール:medipd@qub.ac.uk

研究場所

      • Belfast、イギリス、BT12 6BA
        • 募集
        • Remote assessments from Centre for Public Health, Queens University Belfast
        • コンタクト:
          • Nicola Ann Ward, PhD, MSci
          • 電話番号:07823368444
          • メール:medipd@qub.ac.uk
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Self-reported idiopathic Parkinson's disease
  • Age 18 years or older
  • Community-dwelling and resident in the United Kingdom
  • Access to an internet-enabled device and an active email address
  • Mediterranean Diet Score ≤7/13, indicating low adherence to a Mediterranean diet
  • Proficient in English
  • Able to provide informed consent

Exclusion Criteria:

  • Atypical or secondary parkinsonism
  • Living in an institution
  • Self-reported body mass index <18.5 kg/m²
  • High risk of malnutrition, defined as MUST score ≥2
  • Receiving prescribed nutritional support
  • Significant cognitive impairment, defined as T-CogS ≤21
  • Pregnancy
  • Active inflammatory bowel disease
  • Dysphagia requiring a pureed diet
  • Food allergies that would prevent adherence to a Mediterranean-style diet
  • Following a vegan diet that would prevent adherence to the study's Mediterranean-style dietary intervention.
  • Current participation in another interventional trial
  • Participation in an investigational medicinal product trial within the previous 90 days where this may affect study outcomes or participant burden
  • Previous participation in a My Moves Matter dietary programme.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:支持療法
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:MediPD Intervention

Participants will receive access to the 12-week MediPD online Mediterranean diet behaviour-change program

MediPD is a 12-week online Mediterranean diet behaviour-change programme for people with Parkinson's disease. It provides personalised educational videos, practical resources, self-monitoring tools, and moderated dietetic support. Participants are encouraged to complete at least one module per week, aiming to adopt and maintain Mediterranean-style dietary changes over 24 weeks.

介入なし:Wait-List Control

Participants will continue to receive their usual care. After completing the final 24-week study assessment, participants in the wait-list control group will be offered access to the MediPD online program for 12 weeks.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in Mediterranean Diet Adherence using a Mediterranean Diet Score at 24 Weeks
時間枠:Baseline to 24 weeks

Adherence to a Mediterranean diet will be assessed using the Mediterranean Diet Score (MDS), derived from a validated 14-item questionnaire. Total scores range from 0 to 14, with higher scores indicating greater adherence to a Mediterranean diet.

Baseline to 24 weeks

二次結果の測定

結果測定
メジャーの説明
時間枠
Change in Mediterranean Diet Adherence using a Mediterranean Diet Score at 12 Weeks
時間枠:Baseline to 12 weeks

Adherence to a Mediterranean diet will be assessed using the Mediterranean Diet Score (MDS), derived from a validated 14-item questionnaire. Total scores range from 0 to 14, with higher scores indicating greater adherence to a Mediterranean diet.

Baseline to 12 weeks
Change in self-reported dietary intake using a 24-hour Dietary Recall
時間枠:Baseline, 12 weeks and 24 weeks.

Dietary intake will be assessed using Intake24, an online 24-hour dietary recall tool. Outcomes will include mean daily intake of energy (kcal/day), foods and macronutrients (g/day and, where appropriate, percentage of energy), and micronutrients (mg or µg/day, as appropriate). Higher values indicate greater intake of food/nutrients.

Baseline, 12 weeks and 24 weeks.
Change in Parkinson's Disease Non-Motor Symptoms using the Movement Disorder Society Non-Motor Rating Scale (MDS-NMS)
時間枠:Baseline, 12 weeks and 24 weeks.

Non-motor symptoms will be assessed using the validated 52-item, rater-administered Movement Disorder Society Non-Motor Rating Scale (MDS-NMS). Total scores range from 0 to 832, with higher scores indicating a greater non-motor symptom burden and a worse outcome.

Baseline, 12 weeks and 24 weeks.
Change in reported Gastrointestinal Symptoms using the Gastrointestinal Symptom Rating Scale (GSRS)
時間枠:Baseline, 12 weeks and 24 weeks.

Gastrointestinal symptoms will be assessed using the 15-item Gastrointestinal Symptom Rating Scale (GSRS). Items are scored from 1 to 7 and summed to provide a total score ranging from 15 to 105. Higher total scores indicate greater gastrointestinal symptom severity and therefore a worse outcome.

Baseline, 12 weeks and 24 weeks.
Change in quality of life using the Parkinson's Disease Questionnaire (PDQ-39)
時間枠:Baseline, 12 weeks and 24 weeks.

Quality of life will be assessed using the 39-item Parkinson's Disease Questionnaire (PDQ-39), which covers eight domains. Each domain score is transformed to a 0-100 scale, and the mean of the eight domain scores provides the PDQ-39 Summary Index. Higher Summary Index scores indicate poorer health-related quality of life and therefore a worse outcome.

Baseline, 12 weeks and 24 weeks.
Change in cognitive function using TestMyBrain cognitive test battery
時間枠:Baseline, 12 weeks and 24 weeks.

Cognitive function will be assessed using the TestMyBrain cognitive test battery, comprising Verbal Paired Associates, Visual Paired Associates, Backward Digit Span, Digit Symbol Matching, and Trail Making A and B. Each test score will be converted to a z-score and oriented so that higher scores consistently indicate better performance. The z-scores will be summed to provide an overall cognitive composite score with higher scores indicating better cognitive function.

Baseline, 12 weeks and 24 weeks.

その他の成果指標

結果測定
メジャーの説明
時間枠
Change in whole-gut transit time using the Blue Poop Challenge (optional assessment)
時間枠:Baseline, 12 weeks and 24 weeks.

Consenting participants who opt into this assessment will consume a standardised food-grade blue dye preparation and record the date and time of ingestion and the first appearance of blue colouring in their stool. Whole-gut transit time will be calculated as the elapsed time in hours between ingestion and the first appearance of blue stool. Higher values indicate a longer, slower whole-gut transit time.

Baseline, 12 weeks and 24 weeks.
Intervention acceptability using a study-specific semi-structured qualitative interview
時間枠:Week 24

Intervention acceptability will be explored through a study-specific semi-structured interview with a purposive sample of approximately 10-15 participants from the MediPD intervention group. Interviews will explore satisfaction and acceptability, relevance and usefulness, engagement, feasibility, platform usability, perceived impact, participant burden, barriers and facilitators, and suggestions for improvement. Interviews will be audio-recorded, transcribed verbatim and analysed qualitatively to identify key themes. This assessment does not generate a numerical score and therefore has no minimum or maximum value.

Week 24

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Claire T McEvoy, PhD, Mphil, RD、Queens University Belfast

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年10月10日

一次修了 (推定)

2027年8月30日

研究の完了 (推定)

2028年2月29日

試験登録日

最初に提出

2026年9月10日

QC基準を満たした最初の提出物

2026年9月17日

最初の投稿 (実際)

2026年9月24日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月26日

QC基準を満たした最後の更新が送信されました

2026年10月22日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する